Advertisement
Screener

Lineage Cell Therapeutics, Inc. (LCTX) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Lineage Cell Therapeutics, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Lineage Cell Therapeutics, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $18.92M went out.
  • Fiscal year ended 2025-12-31: from investing, $13.46M went out.
  • Fiscal year ended 2025-12-31: from financing, $26.95M came in.
  • Fiscal year ended 2025-12-31: change in cash, $5.03M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingDebt paid backCommercial paperStaff share taxNew shares soldNot split outChange in cash
2025-12-31-$18.92M-$13.46M-$16.00K$1.25M$25.72M*-$5.03M
2024-12-31-$23.09M-$2.31M-$23.00K$229.00K$35.65M*$10.36M
2023-12-31-$28.57M$46.45M-$37.00K$6.63M$24.06M
2022-12-31$1.06M-$46.16M-$17.00K$148.00K$1.50M*-$44.34M
2021-12-31-$23.56M$9.74M$30.86M$6.07M*$23.09M
2020-12-31-$19.75M$13.04M$5.13M$24.74M*$23.09M
2019-12-31-$31.95M$16.96M-$70.00K$103.00K$584.00K*-$14.30M
2018-12-31-$30.88M$11.82M-$101.00K$5.88M*-$13.29M
2017-12-31-$30.52M-$10.22M-$49.00K$48.88M$6.57M*$14.75M
2016-12-31-$42.33M-$10.89M$20.13M$12.66M*-$20.14M
2015-12-31-$44.54M-$7.44M$35.47M$29.30M*$12.74M
2014-12-31-$38.85M-$1.01M$44.15M$19.47M*$23.99M
2013-12-31-$29.51M-$3.67M$25.94M$8.32M*$1.15M
2012-12-31-$19.68M-$104.69K$1.13M$782.10K*-$17.86M
2011-12-31-$13.59M-$1.20M$0.00*$0.00$3.86M*-$11.11M
2010-12-31-$7.73M$3.20M$0.00*$0.00$25.77M*$21.14M
2009-12-31-$4.26M-$46.23K$2.05M*$8.00M$6.44M*$12.18M

Each quarter (3 month)

Quarter endRunning the businessFrom investingDebt paid backStaff share taxNew shares soldNot split outChange in cash
2026-06-30-$7.24M*$3.96M*$0.00*$6.00K*$4.46M*
2026-03-31-$8.08M-$2.33M-$40.00K$227.00K$5.37M*-$4.85M
2025-12-31-$4.88M*-$15.33M*-$1.00K*$763.00K*$19.62M*
2025-09-30-$3.62M*-$12.00K*$0.00*$487.00K*$1.35M*
2025-06-30-$5.54M*-$14.00K*$0.00*$0.00*
2025-03-31-$4.89M$1.90M-$15.00K$0.00$5.06M*$1.99M
2024-12-31-$6.35M*$2.63M*$0.00*$0.00*$21.73M*
2024-09-30-$5.79M*$3.89M*$0.00*$0.00*
2024-06-30-$5.18M*-$8.79M*$0.00*$87.00K*
2024-03-31-$5.78M-$38.00K-$23.00K$14.04M$8.13M
2023-12-31-$6.02M*$9.74M*$0.00*$0.00*
2023-09-30-$5.04M*$2.12M*$0.00*$836.00K*
2023-06-30-$6.27M*$19.16M*$0.00*$5.80M
2023-03-31-$11.24M$15.43M-$37.00K$0.00$4.08M
2022-12-31-$8.30M*-$5.10M*$0.00*
2022-09-30-$5.48M*-$40.91M*$0.00*$964.00K*
2022-06-30-$7.06M*-$97.00K*$0.00*
2022-03-31$21.90M-$46.00K$148.00K$22.33M
2021-12-31-$5.87M*-$146.00K*$124.00K*$830.00K*
2021-09-30-$4.85M*-$68.00K*$2.93M*$791.00K*
2021-06-30-$5.42M*-$115.00K*$7.94M*$3.35M*
2021-03-31-$7.42M$10.07M$19.87M$1.09M*$23.53M
2020-12-31-$5.64M*$902.00K*$4.81M*
2020-09-30-$4.85M*$178.00K*$24.56M*
2020-06-30-$4.24M*$6.70M*$503.00K*
2020-03-31-$5.03M$5.26M$293.00K
2019-12-31-$5.52M*$720.00K*$0.00*$0.00*
2019-09-30-$7.44M*$13.48M*$0.00*
2019-06-30-$9.67M*-$194.00K*-$18.00K*
2019-03-31-$9.31M$2.95M-$52.00K$658.00K*-$5.71M
2018-12-31-$5.81M*$9.78M*$0.00*
2018-09-30-$7.33M*-$138.00K*
2018-06-30-$7.40M*-$41.00K*$4.90M*
2018-03-31-$10.34M$2.21M$633.00K*-$7.43M
2017-12-31-$5.67M*-$583.00K*$28.75M*-$2.37M*$20.18M*
2017-09-30-$7.68M*-$258.00K*$0.00*$4.99M*$2.11M*
2017-06-30-$9.06M*-$230.00K*$0.00*$4.92M*-$9.27M*
2017-03-31-$8.10M-$9.15M$20.13M-$1.03M*$1.73M
2016-12-31-$8.85M*-$409.00K*$0.00*$843.00K*-$8.36M*
2016-09-30-$8.91M*-$464.00K*$2.63M*$9.58M*$2.75M*
2016-06-30-$10.25M*-$8.35M*$17.50M*$1.47M*$570.00K*
2016-03-31-$14.31M-$1.67M$0.00$764.00K*-$15.10M
2015-12-31-$13.95M*-$2.59M*$26.89M*$2.65M*$12.85M*
2015-09-30-$11.56M*-$2.03M*-$3.01M*$14.17M*-$2.09M*
2015-06-30-$9.97M*-$2.45M*$6.09M*$12.30M*$5.63M*
2015-03-31-$9.07M-$373.00K$5.50M-$3.66M
2014-12-31-$9.11M*-$209.00K*$29.43M*$1.55M*$22.07M*
2014-09-30-$8.61M*-$92.00K*$0.00*-$8.31M*
2014-06-30-$10.78M*-$179.38K*$6.54M*$13.52M*$9.08M*
2014-03-31-$10.36M-$527.62K$8.18M$3.95M*$1.14M
2013-12-31-$8.63M*-$1.66M*$2.13M*$7.00M*-$1.22M*
2013-09-30-$6.42M*-$1.22M*$0.00*-$7.59M*
2013-06-30-$7.44M*-$239.00K*$12.11M*$4.41M*
2013-03-31-$7.02M-$550.55K$11.70M$1.41M*$5.55M
2012-12-31-$5.00M*-$195.91K*$1.13M*-$3.48M*
2012-09-30-$5.01M*-$51.65K*$0.00*-$4.83M*
2012-06-30-$3.96M*$260.00K*$0.00*-$3.83M*
2012-03-31-$5.72M-$117.13K$0.00-$5.72M
2011-12-31-$3.85M*-$180.00K*-$3.21M*-$4.02M*
2011-09-30-$3.60M*-$242.56K*$3.00M*-$1.15M*
2011-06-30-$2.80M*-$242.17K*-$2.76M*
2011-03-31-$3.36M-$537.98K$689.83K*-$3.19M
2010-12-31-$2.78M*$3.90M*$0.00*$7.09M*$8.14M*
2010-09-30-$1.99M*-$271.67K*$0.00*$9.63M*$7.35M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
Alector, Inc. (ALEC)United States$0.213B-1.90
Invivyd, Inc. (IVVD)United States$0.270B-2.42
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51